Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2024 16:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today...
May 28, 2024 02:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH)

Evkeeza is een eerste klasse geneesmiddel dat wordt aanbevolen voor vergoeding door het Nederlands Agentschap voor Gezondheidstechnologie voor de behandeling van HoFH bij patiënten ≥ 5 jaar oud ...
May 17, 2024 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
May 07, 2024 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference

NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
May 02, 2024 16:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million,...
April 30, 2024 16:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to...
April 30, 2024 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies...
April 25, 2024 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
April 19, 2024 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
April 15, 2024 07:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170 Additional long-term data in...